Results 221 to 230 of about 89,572 (287)

Combined Docetaxel-Loaded Perfluorocarbon Nanodroplets with Ultrasound-Mediated Blood-Brain Barrier Disruption for Effective Glioblastoma Treatment in Mice Model. [PDF]

Int J Nanomedicine
Bérard C, Desgranges S, Dumas N, Novell A, Selingue E, Hamimed M, Chevallier OP, Truillet C, Larrat B, Taulier N, Correard F, Contino-Pépin C, Estève MA.   +12 more
europepmc   +1 more source

DRAM1‐defined autophagy‐JAK‐STAT‐Tregs axis drives immunosuppression and predicts immunotherapy response in pan‐cancer

Clinical and Translational Discovery, Volume 6, Issue 3, June 2026.
Tumour‐intrinsic DRAM1, induced by DNA damage and IFN‐γ, activates an autophagy/JAK‐STAT axis that recruits Tregs, causing CD8+ T cell exhaustion and establishing a self‐sustaining, immunotherapy‐resistant “cold” tumour microenvironment. Abstract Background DNA damage‐regulated autophagy modulator 1 (DRAM1) is a lysosomal protein involved in autophagy ...
Jinchun Wu, Hailing Yang, Jingjing Cao, Min Yang, Wanqiao Cao, Yonglei Liu, Yunfeng Cheng, Fanli Hua   +7 more
wiley   +1 more source

Rezvilutamide in combination with androgen deprivation therapy (ADT) with or without docetaxel in the neoadjuvant treatment of oligometastatic prostate cancer (REDOOM): study protocol for an open-label, parallel-cohort, multicentre clinical study. [PDF]

BMJ Open
Chen ZJ, Zhu XX, Huang H, Ding YZ, Zhuang YD, Wang L, Li P, Yu KY, Chen HD, Wang HL, Li HY, Cai B, Deng ZX, Pan Y, Yang Y, Li P, Huang KT, Ji XW, Lin Q, Chen W.   +19 more
europepmc   +1 more source

Anticonvulsant effects of novel and repurposed drugs on docetaxel-induced neuropathy in C. elegans. [PDF]

PLoS One
Gonzalez-Lerma PX, Lloyd C, Park SJ, Dawson-Scully K.   +3 more
europepmc   +1 more source

FOXJ1 mediates taxane resistance through regulation of microtubule dynamics. [PDF]

Nat Commun
Xie F, Gjyrezi A, Fein D, Labaf M, Poluben L, Ersoy-Fazlioglu B, Dennehy CM, Voznesensky O, Gad A, Corey E, Varkaris A, Einstein DJ, Bhatt RS, Giannakakou P, Balk SP.   +14 more
europepmc   +1 more source

Screening anticancer peptides performance in organotypic prostate tumor‐stroma 3D models

International Journal of Cancer, Volume 158, Issue 11, Page 2936-2946, 1 June 2026.
What's new? Peptide‐based drugs have emerged as promising anticancer therapies for their potential to disrupt protein–protein interactions. In this study, the authors developed a physiomimetic human 3D prostate cancer spheroid model to assess the efficacy of the CAVPENET peptide in inhibiting tumor growth. Upon incubation with CAVPENET, prostate cancer
Bárbara Matos, Maria V. Monteiro, Matilde R. Lagarto, John Howl, Carmen Jerónimo, Vítor M. Gaspar, João F. Mano, Margarida Fardilha   +7 more
wiley   +1 more source

Real-World Outcomes and Safety of PD-1 Blockade Rechallenge Strategies After Prior Immunotherapy in Advanced NSCLC: A Retrospective Cohort Study. [PDF]

Drug Des Devel Ther
Zheng LJ, Shen YL, Zhao HW, Ma YC, Wang AF.   +4 more
europepmc   +1 more source

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

iMetaMed, Volume 2, Issue 2, June 2026.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen, Hui Chen, Vijaya Raghavan, Jing Huang, Jin Wang   +4 more
wiley   +1 more source

GUTK induces apoptosis in reactivating quiescent prostate cancer cells <i>via</i> Aurora A-mediated stabilization of SOD2. [PDF]

iScience
Wang Y, Li Y, Jiang X, Chen X, Liu M, Ren H, Zhang Y, Dai R, Xi Z, Xu H.   +9 more
europepmc   +1 more source

Comparative Genomic Profiling and Prognostic Impact in Recurrent and/or Metastatic Hypopharyngeal and Esophageal Squamous Cell Carcinoma

Laryngoscope Investigative Otolaryngology, Volume 11, Issue 3, June 2026.
ABSTRACT Objective This study aimed to characterize the mutational profile of recurrent and/or metastatic esophageal squamous cell carcinoma (ESCC) and hypopharyngeal squamous cell carcinoma (HPSCC). Methods Data from 1319 consecutive patients with ESCC and 195 patients with HPSCC registered in the Center for Cancer Genomics and Advanced Therapeutics ...
Hiromi Nagano, Satoshi Kiyama, Takayuki Kyutoku, Hayato Matsumoto, Masaru Yamashita   +4 more
wiley   +1 more source